Client News

Secarna Pharmaceuticals enters discovery and co-development agreement with Scenic Biotech to develop disease-modifying oligonucleotide therapy against a novel drug target

Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma

smartbax announces a €4.7 M Pre-Series A round to advance novel antibiotic compound through preclinical stage

Ipsen to acquire ImCheck Therapeutics, in Andera Partners’ portfolio, expanding its leadership in oncology, strengthening its pipeline

InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe

ActiTrexx completes treatment of last patient with novel regulatory T cell therapy against Graft-versus-Host Disease

Andera Partners co-leads €105 million Series A round for Adcytherix, its first investment from the BioDiscovery 7 fund

TVM CAPITAL LIFE SCIENCE PORTFOLIO COMPANY SMART REPORTING TO ACQUIRE FLUENCY FOR IMAGING – UNITING TO CREATE JACOBIAN AND ACCELERATE AI-POWERED REPORTING

Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America